Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17257490 | 1.00 | HSD17B10 (0.34) | HSD17B10LMNAGAAMAPT | |
| SCHEMBL17257574 | 0.84 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL17257573 | 0.84 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL17256744 | 0.83 | RBBP9 (0.35) | HSD17B10MAPT | |
| SCHEMBL17256745 | 0.83 | RBBP9 (0.35) | HSD17B10MAPT | |
| SCHEMBL17257057 | 0.78 | MAPT (0.33) | LMNAMAPT | |
| SCHEMBL17257054 | 0.78 | MAPT (0.33) | LMNAMAPT | |
| SCHEMBL17257628 | 0.77 | L3MBTL1 (0.51) | HSD17B10LMNAGAAMAPT | |
| SCHEMBL17257372 | 0.75 | ALDH1A1 (0.41) | LMNAMAPT | |
| SCHEMBL12743239 | 0.74 | ALDH1A1 (0.38) | HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | claimed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | claimed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | claimed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | claimed |
| EP-3143055-B1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORP (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | PAM, PPOX, MB | HSD17B10 3092/4885LMNA 383/4885GAA 2104/4885 |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | PAM, PPOX, MB | HSD17B10 3092/4885LMNA 383/4885GAA 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.